版本:
中国

BRIEF-Bristol-Myers Squibb and Seattle Genetics expand collaboration to evaluate combination of opdivo and adcetris

June 2 Bristol-myers Squibb Co

* Bristol-Myers Squibb and Seattle Genetics expand clinical collaboration to evaluate combination of opdivo (nivolumab) and adcetris® (brentuximab vedotin) in pivotal phase 3 clinical trial in relapsed hodgkin lymphoma

* Bristol-Myers Squibb Co - ‍pivotal phase 3 trial planned for mid-2017​

* Bristol-Myers - phase 3 trial to evaluate adcetris alone or with opdivo in relapsed/refractory or transplant-ineligible advanced classical hodgkin lymphoma

* Bristol-Myers Squibb- in addition to planned trial, adcetris, opdivo being evaluated as combination therapy in multiple ongoing phase 1/2 clinical trials

* Bristol-Myers Squibb Co -adcetris, opdivo combination being evaluated for older hl patients,relapsed/refractory classical hl for children, adolescents Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐